MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.50 and traded as high as $1.62. MediciNova shares last traded at $1.56, with a volume of 16,286 shares changing hands.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on MediciNova in a research note on Thursday. They set a “hold” rating on the stock.
Check Out Our Latest Stock Analysis on MNOV
MediciNova Stock Performance
MediciNova (NASDAQ:MNOV – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. As a group, equities analysts forecast that MediciNova, Inc. will post -0.23 EPS for the current fiscal year.
MediciNova Company Profile
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Stories
- Five stocks we like better than MediciNova
- Stock Splits, Do They Really Impact Investors?
- What a Trump Win Looks Like for the Market Now and Into 2025
- Breakout Stocks: What They Are and How to Identify Them
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What Are Dividends? Buy the Best Dividend Stocks
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.